BR112013022556A2 - composição farmacêutica aquosa semissólida contendo tapentadol - Google Patents
composição farmacêutica aquosa semissólida contendo tapentadolInfo
- Publication number
- BR112013022556A2 BR112013022556A2 BR112013022556A BR112013022556A BR112013022556A2 BR 112013022556 A2 BR112013022556 A2 BR 112013022556A2 BR 112013022556 A BR112013022556 A BR 112013022556A BR 112013022556 A BR112013022556 A BR 112013022556A BR 112013022556 A2 BR112013022556 A2 BR 112013022556A2
- Authority
- BR
- Brazil
- Prior art keywords
- semi
- pharmaceutical composition
- composition containing
- aqueous pharmaceutical
- solid aqueous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161449329P | 2011-03-04 | 2011-03-04 | |
| EP11003603 | 2011-05-03 | ||
| PCT/EP2012/000906 WO2012119729A1 (en) | 2011-03-04 | 2012-03-02 | Semisolid aqueous pharmaceutical composition containing tapentadol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112013022556A2 true BR112013022556A2 (pt) | 2016-12-06 |
| BR112013022556A8 BR112013022556A8 (pt) | 2018-01-16 |
Family
ID=44652117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013022556A BR112013022556A8 (pt) | 2011-03-04 | 2012-03-02 | composição farmacêutica aquosa semissólida contendo tapentadol, seu uso e uso de tapentadol |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US9446008B2 (pt) |
| EP (3) | EP2680834B1 (pt) |
| JP (3) | JP6027549B2 (pt) |
| KR (2) | KR101911362B1 (pt) |
| CN (1) | CN103501774A (pt) |
| AU (2) | AU2012224954C1 (pt) |
| BR (1) | BR112013022556A8 (pt) |
| CA (1) | CA2828637C (pt) |
| CY (1) | CY1119725T1 (pt) |
| DK (1) | DK2680834T3 (pt) |
| EA (2) | EA025194B1 (pt) |
| ES (2) | ES2654407T3 (pt) |
| HR (1) | HRP20171836T1 (pt) |
| HU (1) | HUE037491T2 (pt) |
| IL (2) | IL227826B (pt) |
| LT (1) | LT2680834T (pt) |
| MX (1) | MX344473B (pt) |
| NO (1) | NO2680834T3 (pt) |
| PL (1) | PL2680834T3 (pt) |
| PT (2) | PT3766489T (pt) |
| RS (1) | RS56692B1 (pt) |
| SI (1) | SI2680834T1 (pt) |
| WO (1) | WO2012119729A1 (pt) |
| ZA (1) | ZA201306480B (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9446008B2 (en) * | 2011-03-04 | 2016-09-20 | Gruenenthal Gmbh | Semisolid aqueous pharmaceutical composition containing tapentadol |
| SI3287123T1 (sl) | 2011-03-04 | 2020-07-31 | Gruenenthal Gmbh | Vodna farmacevtska formulacija tapentadola za peroralno uporabo |
| US9395306B2 (en) | 2011-08-05 | 2016-07-19 | Halliburton Energy Services, Inc. | Methods for monitoring fluids within or produced from a subterranean formation during acidizing operations using opticoanalytical devices |
| US8997860B2 (en) | 2011-08-05 | 2015-04-07 | Halliburton Energy Services, Inc. | Methods for monitoring the formation and transport of a fracturing fluid using opticoanalytical devices |
| US8619256B1 (en) | 2012-09-14 | 2013-12-31 | Halliburton Energy Services, Inc. | Systems and methods for monitoring the properties of a fluid cement composition in a flow path |
| US20140076550A1 (en) | 2012-09-14 | 2014-03-20 | Halliburton Energy Services, Inc. | Systems and Methods for Detecting Microannulus Formation and Remediation |
| US9228940B2 (en) | 2012-09-14 | 2016-01-05 | Halliburton Energy Services, Inc. | Systems, methods, and apparatuses for in situ monitoring of cement fluid compositions and setting processes thereof |
| US20160136112A1 (en) * | 2013-08-02 | 2016-05-19 | Ratiopharm Gmbh | Composition comprising tapentadol in a dissolved form |
| EP2845625A1 (en) | 2013-09-04 | 2015-03-11 | Grünenthal GmbH | Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome |
| MX2017012312A (es) * | 2015-03-27 | 2018-01-18 | Gruenenthal Gmbh | Formulacion estable para administracion parenteral de tapentadol. |
| BR112019005439A2 (pt) * | 2016-09-23 | 2019-06-18 | Gruenenthal Gmbh | formulação estável para administração parenteral de tapentadol |
| WO2020020879A1 (en) * | 2018-07-24 | 2020-01-30 | Dr. August Wolff Gmbh & Co. Kg Arzneimittel | Topical emulsion of an anticholinergic compound |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775678A (en) * | 1984-10-01 | 1988-10-04 | Schering Corporation | Clotrimazole cream |
| DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| US6183758B1 (en) * | 1998-01-29 | 2001-02-06 | Highland Laboratories, Inc. | Phytochemicals, nutrients & medication absorption &/or treatment |
| US6399087B1 (en) | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
| DE10109763A1 (de) | 2001-02-28 | 2002-09-05 | Gruenenthal Gmbh | Pharmazeutische Salze |
| US20050176790A1 (en) * | 2001-02-28 | 2005-08-11 | Johannes Bartholomaus | Pharmaceutical salts |
| PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| CA2479350A1 (en) | 2002-03-15 | 2003-09-25 | Cypress Bioscience, Inc. | Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes |
| US20030191187A1 (en) | 2002-04-01 | 2003-10-09 | Lee Fang Yu | Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same |
| JP2006503047A (ja) | 2002-09-13 | 2006-01-26 | サイデックス・インコーポレイテッド | 誘導シクロデキストリンにより安定化された水性フィル組成物を含有するカプセル |
| US20040180915A1 (en) | 2003-03-14 | 2004-09-16 | Xanodyne Pharmacal, Inc. | Methadone-containing compositions for parenteral administration and method of use thereof |
| JP2007538091A (ja) | 2004-05-17 | 2007-12-27 | ファーマコフォア・インコーポレイテッド | 痛みを処置または予防するための組成物および方法 |
| PT1612203E (pt) | 2004-06-28 | 2007-08-20 | Gruenenthal Gmbh | ''formas cristalinas de cloridrato de (-) - (1r,2r) - 3 -(3-dimetilamino-l-etil - 2 - metilpropil) fenol'' |
| AU2005259478B2 (en) | 2004-07-01 | 2010-07-15 | Gruenenthal Gmbh | Oral dosage form safeguarded against abuse containing (1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
| WO2006116626A2 (en) | 2005-04-28 | 2006-11-02 | Theraquest Biosciences Llc | Methods and compositions for treating pain |
| TWI329334B (en) | 2005-12-02 | 2010-08-21 | Chung Shan Inst Of Science | Manufacture method of electromagnetic interference layer for the plasma display panel |
| EP2010145A2 (en) * | 2006-04-25 | 2009-01-07 | Croda, Inc. | Modification of percutaneous absorption of topically active materials |
| ES2358763T3 (es) * | 2006-04-28 | 2011-05-13 | Grünenthal GmbH | Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y un nsaid. |
| CA2650423C (en) | 2006-04-28 | 2014-08-12 | Gruenenthal Gmbh | Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and paracetamol |
| WO2008012283A1 (en) | 2006-07-24 | 2008-01-31 | Janssen Pharmaceutica Nv | Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine |
| DE102007012165A1 (de) | 2007-03-12 | 2008-09-18 | Grünenthal GmbH | Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes |
| EP1985292A1 (en) | 2007-04-23 | 2008-10-29 | Grünenthal GmbH | Titration of tapentadol |
| KR101607112B1 (ko) | 2007-11-23 | 2016-03-29 | 그뤼넨탈 게엠베하 | 타펜타돌 조성물 |
| EP2249811A1 (en) | 2008-01-25 | 2010-11-17 | Grünenthal GmbH | Pharmaceutical dosage form |
| NZ592437A (en) | 2008-10-30 | 2013-03-28 | Gruenenthal Chemie | A dosage form comprising tapentadol and an opioid antagonist |
| WO2010100477A2 (en) | 2009-03-03 | 2010-09-10 | Shire Llc | Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof |
| US20100272815A1 (en) * | 2009-04-28 | 2010-10-28 | Actavis Group Ptc Ehf | Amorphous form of tapentadol hydrochloride |
| WO2011083304A1 (en) * | 2010-01-05 | 2011-07-14 | Shire Llc | Prodrugs of opioids and uses thereof |
| ES2829386T3 (es) * | 2010-03-30 | 2021-05-31 | Phosphagenics Ltd | Parche de administración transdérmica |
| GB201006200D0 (en) | 2010-04-14 | 2010-06-02 | Ayanda As | Composition |
| US20120270848A1 (en) * | 2010-10-22 | 2012-10-25 | Galleon Pharmaceuticals, Inc. | Novel Compositions and Therapeutic Methods Using Same |
| US9446008B2 (en) | 2011-03-04 | 2016-09-20 | Gruenenthal Gmbh | Semisolid aqueous pharmaceutical composition containing tapentadol |
-
2012
- 2012-03-02 US US13/410,837 patent/US9446008B2/en active Active
- 2012-03-02 ES ES12710026.1T patent/ES2654407T3/es active Active
- 2012-03-02 LT LTEP12710026.1T patent/LT2680834T/lt unknown
- 2012-03-02 SI SI201231143T patent/SI2680834T1/en unknown
- 2012-03-02 EP EP12710026.1A patent/EP2680834B1/en active Active
- 2012-03-02 RS RS20171334A patent/RS56692B1/sr unknown
- 2012-03-02 DK DK12710026.1T patent/DK2680834T3/en active
- 2012-03-02 NO NO12710026A patent/NO2680834T3/no unknown
- 2012-03-02 CA CA2828637A patent/CA2828637C/en not_active Expired - Fee Related
- 2012-03-02 MX MX2013010100A patent/MX344473B/es active IP Right Grant
- 2012-03-02 JP JP2013555798A patent/JP6027549B2/ja not_active Expired - Fee Related
- 2012-03-02 EA EA201300988A patent/EA025194B1/ru not_active IP Right Cessation
- 2012-03-02 EP EP20188822.9A patent/EP3766489B1/en active Active
- 2012-03-02 KR KR1020137026185A patent/KR101911362B1/ko active Application Filing
- 2012-03-02 EP EP17189139.3A patent/EP3290029B1/en active Active
- 2012-03-02 WO PCT/EP2012/000906 patent/WO2012119729A1/en active Application Filing
- 2012-03-02 ES ES20188822T patent/ES2910085T3/es active Active
- 2012-03-02 CN CN201280011678.9A patent/CN103501774A/zh active Pending
- 2012-03-02 PL PL12710026T patent/PL2680834T3/pl unknown
- 2012-03-02 PT PT201888229T patent/PT3766489T/pt unknown
- 2012-03-02 BR BR112013022556A patent/BR112013022556A8/pt not_active Application Discontinuation
- 2012-03-02 KR KR1020187029861A patent/KR102039320B1/ko active IP Right Grant
- 2012-03-02 EA EA201600442A patent/EA033171B1/ru not_active IP Right Cessation
- 2012-03-02 PT PT127100261T patent/PT2680834T/pt unknown
- 2012-03-02 AU AU2012224954A patent/AU2012224954C1/en active Active
- 2012-03-02 HU HUE12710026A patent/HUE037491T2/hu unknown
-
2013
- 2013-08-06 IL IL227826A patent/IL227826B/en active IP Right Grant
- 2013-08-28 ZA ZA2013/06480A patent/ZA201306480B/en unknown
-
2016
- 2016-08-10 US US15/232,841 patent/US20160346229A1/en not_active Abandoned
- 2016-10-12 JP JP2016200663A patent/JP6259042B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-04 AU AU2017200040A patent/AU2017200040B2/en active Active
- 2017-11-24 HR HRP20171836TT patent/HRP20171836T1/hr unknown
- 2017-11-29 JP JP2017228602A patent/JP6670283B2/ja not_active Expired - Fee Related
-
2018
- 2018-01-03 CY CY20181100006T patent/CY1119725T1/el unknown
- 2018-01-10 US US15/867,330 patent/US20180133174A1/en not_active Abandoned
- 2018-03-26 IL IL258357A patent/IL258357A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201700008B (it) | Composizione farmaceutica | |
| BR112013022556A2 (pt) | composição farmacêutica aquosa semissólida contendo tapentadol | |
| DK2694038T3 (da) | Farmaceutisk sammensætning | |
| DK3181122T3 (da) | Farmaceutisk dasatinib-sammensætning | |
| CO6852076A2 (es) | Composiciones farmacéuticas inhalables | |
| BR112014003052A2 (pt) | composições farmacêuticas | |
| BR112015002738A2 (pt) | composto , e , composição farmacêutica | |
| DK3246018T3 (da) | Farmaceutisk sammensætning | |
| CO6930367A2 (es) | Composiciones farmaceúticas | |
| SMT201700110B (it) | Composizione immunogena | |
| BR112015004936A2 (pt) | composição farmacêutica revestida contendo regorafenib | |
| DK2882433T3 (da) | Antimikrobielle sammensætninger omfattende glycerylnitrater | |
| BR112013014644A2 (pt) | composição farmacêutica e complexo | |
| EE201300005A (et) | Ravimkoostis | |
| CO6940426A2 (es) | Formulaciones farmacéuticas | |
| DK2897594T3 (da) | Farmaceutisk sammensætning | |
| DK2815752T3 (da) | Oral farmaceutisk sammensætning | |
| SMT201600097B (it) | Composizione farmaceutica liquida che comprende nitisone | |
| BR112014009319A2 (pt) | compostos farmacêuticos | |
| CO7010828A2 (es) | Preparación farmacéutica que comprende ßciclodextrina sustituida | |
| CO6920289A2 (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib. | |
| BR112015003116A2 (pt) | preparação farmacêutica sólida contendo levotiroxina | |
| BR112012029461A2 (pt) | composição farmacêutica contendo solifenacina | |
| BR112015014078A2 (pt) | composição farmacêutica oftalmológica tópica que contém regorefenib | |
| BR112014016122A8 (pt) | composto, e, composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |